Literature DB >> 19060419

Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study.

Satoshi Ogawa1, Takeshi Yamashita, Tsutomu Yamazaki, Yoshifusa Aizawa, Hirotsugu Atarashi, Hiroshi Inoue, Tohru Ohe, Hiroshi Ohtsu, Ken Okumura, Takao Katoh, Shiro Kamakura, Koichiro Kumagai, Yoshihisa Kurachi, Itsuo Kodama, Yukihiro Koretsune, Tetsunori Saikawa, Masayuki Sakurai, Kaoru Sugi, Toshifumi Tabuchi, Haruaki Nakaya, Toshio Nakayama, Makoto Hirai, Masahiko Fukatani, Hideo Mitamura.   

Abstract

Background Although previous clinical trials demonstrated the non-inferiority of a rate control to rhythm control strategy for management of atrial fibrillation (AF), the optimal treatment strategy for paroxysmal AF (PAF) remains unclear. Methods and Results A randomized, multicenter comparison of rate control vs rhythm control in Japanese patients with PAF (the Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) study) was conducted. The primary endpoint was a composite of total mortality, symptomatic cerebral infarction, systemic embolism, major bleeding, hospitalization for heart failure, or physical/psychological disability requiring alteration of treatment strategy. In the study, 823 patients with PAF were followed for a mean period of 578 days. The primary endpoint occurred in 64 patients (15.3%) assigned to rhythm control and in 89 patients (22.0%) to rate control (P=0.0128). No significant differences between the treatment strategies were observed in the incidences of death, stroke, bleeding and heart failure. Meanwhile, significantly fewer patients requested changes of assigned treatment strategy in the rhythm control vs the rate control group, which was accompanied by improvement in AF-specific quality of life scores. Conclusion The J-RHYTHM study showed that rhythm control was associated with fewer primary endpoints than rate control. However, mortality and cardiovascular morbidity were not affected by the treatment strategy (umin-CTR No. C000000106).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19060419     DOI: 10.1253/circj.cj-08-0608

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  32 in total

1.  [Rate and rhythm control in atrial fibrillation : pharmacological approaches].

Authors:  K F Weipert; D Erkapic; J Schmitt
Journal:  Herz       Date:  2015-02       Impact factor: 1.443

2.  Rate control in atrial fibrillation, insight into the RACE II study.

Authors:  H F Groenveld; H J G M Crijns; J G P Tijssen; M Alings; H L Hillege; Y S Tuininga; M P Van den Berg; D J Van Veldhuisen; I C Van Gelder
Journal:  Neth Heart J       Date:  2013-04       Impact factor: 2.380

3.  Rate versus rhythm control in atrial fibrillation.

Authors:  Grace Frankel; Rejina Kamrul; Lynette Kosar; Brent Jensen
Journal:  Can Fam Physician       Date:  2013-02       Impact factor: 3.275

Review 4.  Atrial fibrillation and heart failure in the elderly.

Authors:  Pedram Kazemian; Gavin Oudit; Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 5.  Should rhythm control be preferred in younger atrial fibrillation patients?

Authors:  Shaojie Chen; Yuehui Yin; Mitchell W Krucoff
Journal:  J Interv Card Electrophysiol       Date:  2012-05-22       Impact factor: 1.900

Review 6.  Anti-Arrhythmic Agents in the Treatment of Atrial Fibrillation.

Authors:  Omar F Hassan; Jassim Al Suwaidi; Amar M Salam
Journal:  J Atr Fibrillation       Date:  2013-06-30

Review 7.  Cost-Effectiveness of Atrial Fibrillation Ablation.

Authors:  Gulmira Kudaiberdieva; Bulent Gorenek
Journal:  J Atr Fibrillation       Date:  2013-06-30

Review 8.  Preventative Measures of Stroke in Patients With Atrial Fibrillation.

Authors:  Ahmed Adlan; Gregory Yh Lip
Journal:  J Atr Fibrillation       Date:  2012-04-14

Review 9.  Early Cardioversion in Atrial Fibrillation: Earlier Is Better, but Not Always and (Maybe) Not Immediately.

Authors:  Paloma G Piña; Alexandru B Chicos
Journal:  Curr Atheroscler Rep       Date:  2017-01       Impact factor: 5.113

Review 10.  Atrial fibrillation in the elderly.

Authors:  Teerapat Nantsupawat; Kenneth Nugent; Arintaya Phrommintikul
Journal:  Drugs Aging       Date:  2013-08       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.